Literature DB >> 29373136

Impact of a novel contrast reduction system on contrast savings in coronary angiography - The DyeVert randomised controlled trial.

Steffen Desch1, Georg Fuernau2, Janine Pöss2, Roza Meyer-Saraei2, Mohammed Saad2, Ingo Eitel2, Holger Thiele3, Suzanne de Waha2.   

Abstract

AIMS: The most prominent procedure-related and thus modifiable risk factor for contrast-induced acute kidney injury is contrast media (CM) volume. The DyeVert™ system has been designed to reduce the amount of CM. The primary objective of this randomised controlled trial was thus to examine whether the novel DyeVert™ contrast reduction system (Osprey Medical Inc., Minnetonka, MN, USA) leads to a reduction in CM volume in patients undergoing diagnostic coronary angiography.
METHODS: Patients scheduled for a diagnostic coronary angiogram were randomised to angiography with or without the DyeVert™ system. The primary efficacy endpoint was mean CM volume. Image quality was evaluated by an independent reviewer blinded to treatment allocation.
RESULTS: A total of 96 patients underwent randomisation. Baseline characteristics were well balanced between groups. Use of the DyeVert™ system resulted in a significant 41.0% reduction in CM volume (36.9±10.9mL versus 62.5±12.7mL, p<0.001). Image quality using the DyeVert™ system was non-inferior compared to control (p=0.03). There were no device-related adverse events.
CONCLUSIONS: The DyeVert™ system leads to significant reduction in CM volume in patients undergoing diagnostic coronary angiography, while maintaining image quality.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Contrast media; Contrast reduction; Contrast-induced acute kidney injury; Coronary angiography

Mesh:

Substances:

Year:  2018        PMID: 29373136     DOI: 10.1016/j.ijcard.2017.12.107

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Acute Kidney Injury Following In-Patient Lower Extremity Vascular Intervention: From the National Cardiovascular Data Registry.

Authors:  David M Safley; Adam C Salisbury; Thomas T Tsai; Eric A Secemsky; Kevin F Kennedy; R Kevin Rogers; Faisal Latif; Nicolas W Shammas; Lawrence Garcia; Matthew A Cavender; Kenneth Rosenfield; Anand Prasad; John A Spertus
Journal:  JACC Cardiovasc Interv       Date:  2021-02-08       Impact factor: 11.195

Review 2.  Chronic Total Occlusion Interventions: Update on Current Tips and Tricks.

Authors:  Peter Tajti; Iosif Xenogiannis; Dimitris Karmpaliotis; Khaldoon Alaswad; Farouc A Jaffer; M Nicholas Burke; Imre Ungi; Emmanouil S Brilakis
Journal:  Curr Cardiol Rep       Date:  2018-10-22       Impact factor: 2.931

3.  Early clinical experiences with a novel contrast volume reduction system during invasive coronary angiography.

Authors:  Raphael R Bruno; Amir M Nia; Georg Wolff; Ralf Erkens; Malte Kelm; Ralf Westenfeld; Christian Jung
Journal:  Int J Cardiol Heart Vasc       Date:  2019-05-15

4.  A prospective study of contrast preservation using ultra-low contrast delivery technique versus standard automated contrast injector system in coronary procedures.

Authors:  Adam Stys; Maheedhar Gedela; Udit Bhatnagar; Marian Petrasko; Hazem Dawoud; Tadeusz Malinski; Tomasz Stys
Journal:  Indian Heart J       Date:  2019-09-10

5.  DyeVert™ PLUS EZ System for Preventing Contrast-Induced Acute Kidney Injury in Patients Undergoing Diagnostic Coronary Angiography and/or Percutaneous Coronary Intervention: A UK-Based Cost-Utility Analysis.

Authors:  Mehdi Javanbakht; Mohsen Rezaei Hemami; Atefeh Mashayekhi; Michael Branagan-Harris; Azfar Zaman; Yahya Al-Najjar; Donal O'Donoghue; Farzin Fath-Ordoubadi; Stephen Wheatcroft
Journal:  Pharmacoecon Open       Date:  2020-09

6.  DyeVert Contrast Reduction System Use in Patients Undergoing Coronary and/or Peripheral Angiography: A Systematic Literature Review and Meta-Analysis.

Authors:  Giuseppe Tarantini; Anand Prasad; Sudhir Rathore; Shweta Bansal; Regine Gottfried; Alexander R Rosenkranz; Carlo Briguori; Mohsen Yaghoubi; Atefeh Mashayekhi; Mehdi Javanbakht; Eoin Moloney
Journal:  Front Med (Lausanne)       Date:  2022-04-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.